Form D · Biotechnology
Prana Therapies, Inc.
Encinitas, CA · CIK 0002029240
Offering snapshot reported Aug 10, 2026 · SEC filing
- Reported sold
- $40.2M Offering amount: $40.2M
- Investors reported
- 9 Form D · investor count
- Minimum accepted
- $0 Reported outside-investor minimum
- First sale
- Nov 25, 2025 As reported in this filing
What changed?
Latest filing versus its linked predecessor, where available.
No comparable changes in the displayed metrics.
Filing history
Scroll to see all columns →
| Filed | Filing type | Reported sold | Change vs linked filing | Investors | Source |
|---|---|---|---|---|---|
| Aug 10, 2026 | Initial | $40,226,932 | No comparison | 9 | SEC filing |
| Jul 19, 2024 | Initial | $5,000,000 | No comparison | 2 | SEC filing |
Offering details
- Securities
- Equity, Option to acquire, Security to be acquired
- Exemptions
- 06b
- Duration over one year
- No
- Business combination
- No
- Sales commissions
- $0
- Finders' fees
- $0
- Form D file number
- 021-593683
Includes conversion of $226,935 in simple agreements for future equity.
Source: Form D, filed Aug 10, 2026. Minimum accepted may differ from a standard advertised minimum.
Fund connections
No matching detailed fund disclosure was found in the latest imported ADV filings. This does not establish that the issuer has no adviser.
People & organizations
Current and past Form D appearances. These existing records do not establish a person's current role or uniquely identify them across issuers.
| Name | Reported role |
|---|---|
| Ben Auspitz | Director |
| Alexis Borisy | Director |
| Sheila Gujrathi | Director, Executive |
| Sheila Gujrathi, M.D. | Director, Executive |
| Hector Ortega | Executive |
| Miguel Sanjuan | Director, Executive |
| Ryan Sullivan | Executive |
Issuer details
Industry: Biotechnology (See others in industry)
Address:
378 Neptune Avenue
Encinitas, CA, 92024
Phone: 858-208-0193
Encinitas, CA, 92024
Phone: 858-208-0193